Abstract: Hydroxybenzoate (HB) compounds have shown their significance in inducing apoptosis in primary chronic lymphocytic leukemia (CLL) and cancer cell lines, including HT-1080. The current study focuses on assessing the effects of 2-, 3-and 4-hydroxybenzoate calcium (HBCa) compounds on MCF-10A, MDA-MB231 and MCF-7 epithelial breast cell lines. The HBCa-treated cells were examined using annexin V, to measure apoptosis in the three epithelial breast cell lines, after 48 h of treatment. The results indicated that 0.5 and 2.5 mmol/L of HBCa induced cell death in a dose-dependent manner. The induction of cell death in normal MCF-10A cells was found to be significantly less (p = 0.0003-0.0068), in comparison to the malignant cell lines (MDA-MB231 and MCF-7). HBCa compounds were also found to cause cell cycle arrest in the epithelial breast cells at G1/G0. Furthermore, HBCa compounds induced the upregulation of apoptotic proteins (p53, p21, Bax and caspase-3), as well as the downregulation of the anti-apoptotic protein Bcl-2, which may suggest that apoptosis is induced via the intrinsic pathway. reast cancer is a major global health issue that mainly affects women of all age groups. It is the most common cancer worldwide, with more cases in developing countries than in developed countries [1] . Breast cancer is the second leading cause of cancer death after lung cancer in developed countries (198,000 cases, 15.4%). Incidence rates continue to increase globally except in a few high-income countries. The estimated breast cancer incidents of less developed cases in 2012 were 883,000 (52.8%) and 788,000 more developed cancer cases, with mortality rates of 324,000 (62.1%) and 198,000 (37.9%), respectively [2] . In contrast, more than 60% of breast cancer patients survive in developed countries. Lower survival rates occur in developing countries due to the lack of early detection schemes and diagnosis [3] . Statistics related to breast cancer cases have attracted the attention of various researchers to effectively treat the cancer with chemotherapy. As part of this effort, a large number of compounds have been assessed for their anticancer potential in dif-B
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As part of this effort, a large number of compounds have been assessed for their anticancer potential in dif-B doi: 10.18282/amor.v1.i2. 35 ferent cancer cells [4] [5] [6] [7] . The assessed compounds include hydroxybenzoate (HB), 2-acetylbenzoic acid (2-ABA) or aspirin, and its precursor 2-hydroxybenzoic acid (2-HBA). These compounds showed apoptotic effects at high doses (1-10 mmol/L), which highlight concern regarding their side effects [8, 9] . Our previous studies have shown the induction of apoptosis at lower doses in different cancer cell lines and primary chronic lymphocytic leukaemia (CLL) [4,10−12] . For instance, the morphological and immunological evidence for apoptosis were obtained when 4-hydroxybenzoate zinc (HBZn) or 4-hydroxybenzoate calcium (HBCa) compounds were evaluated [11−13] .
The mechanism of these compounds is to induce apoptosis via the intrinsic pathway involving the upregulation of the expression of p53, Bax and caspase-9 [4, 10, 12] . In parallel, these compounds downregulated Bcl-2, an antiapoptotic protein that is able to suppress cytochrome c release and subsequently caspase-3. The regulation of apoptosis-related proteins in the intrinsic pathway is an important indicator for assessing anticancer compounds' activities. Similar results were obtained in MCF-7 and MDA-MB231 human breast cancer cells when tamoxifen was used [14] .
Hydroxybenzoic acid (HBA) and its metal-bearing analogs are simple compounds with different chemical properties. For example, 2-HBA has a higher acidic content when compared to 3-HBA and 4-HBA. 4HBZn is more potent while 4-HBA is less acidic than the corresponding 2-HBZn and 3-HBZn compounds [12] . The current research examines the cytotoxic effects of three types of HBCa compounds; 2-HBCa, 3-HBCa and 4-HBCa in two epithelial breast cancer cells, MDA-MB231 and MCF-7, and the normal breast cell line MCF-10A, as shown in Figure 1 .
Figure 1 Chemical structures of the three HBCa complexes

Materials and methods
Cell lines:
The mammary epithelial cell lines of both normal (MCF-10A) and cancer (MCF-7 and MDA-MB-231) were obtained from the American Type Culture Collection (ATCC), USA. Chemicals: 2-, 3-, and 4-HBCa were prepared from 2-, 3-and 4-HBA (Sigma-Aldrich, UK) and calcium carbonate (Sigma-Aldrich, UK), respectively through acidbase reaction.
Cell culture
MCF-10A, MDA-MB-231 and MCF-7 cells (ATCC, USA) were cultured in a RPMI-1640 medium. It contained GlutaMAX, 25 mmol/L HEPES buffer (Sigma-Aldrich, UK), 10% fetal bovine serum (FBS) (SigmaAldrich, UK) and 1% penicillin (10,000 U/mL; SigmaAldrich, UK). For MCF-10A cells, the universal medium (1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium (Sigma-Aldrich, UK) were used. This medium was supplemented with 10% FBS, 1% antibiotic-antimitotic, 20 ng/mL epidermal growth factor (EGF), 100 ng/mL cholera toxin, 10 µg/mL insulin and 500 ng/mL hydrocortisone. Then, the cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 .
Detection of cell viability by MTT cell proliferation assay
Breast cells were seeded in a 96-well plate at a density of 2 × 10 5 cell/well in 90 µL optimized medium. The cells were allowed to settle for 24 h before treated with individual dose of HBCa, i.e., 0, 0.1, 0.3, 0. 
Assessment of cell cycle through flow cytometry
Cells (5 × 10 5 cell/mL) were seeded in T-100 flasks (Nunc, Denmark) in 10 mL of fresh optimal medium and allowed to grow to approximately 60%-70% confluence before the cells were subjected to serum starvation for 24 h. The cells were then cultured in optimal medium containing 0.0, 0.5 or 2.5 mmol/L of individual HBCa compounds and incubated for 48 h prior to harvesting and washing with PBS. The harvested cells were centrifuged (300 × g for 5 min) and resuspended in 1 mL of PBS before fixation with 3 mL cold 100% methanol. The fixed cells were then centrifuged (300 × g for 10 min), washed with PBS and re-centrifuged (4000 rpm for 10 min). 1 mL of hypotonic DNA staining buffer (SigmaAldrich, UK) containing PI at 0.01% (w/v), ribonuclease A (RNase A) at 0.002% (w/v), 0.3% (v/v) Triton X-100 and 0.1% (w/v) sodium citrate (pH 7.8) were added to the pellet. The cells were resuspended and incubated at 4°C for 30 min.
Relative DNA contents was assessed as a function of PI labeling according to the method documented by Crissman and Steinkamp [15] which using the Cell-Quest 
Assessment of protein expression by Western blot
Breast cells (5 × 10 5 cell/mL) were seeded in T-100 flask, cultured and treated with HBCa complexes (0, 0.5, 2.5 mmol/L) for 48 h, as described in the previous section. The medium was removed and the cells were washed with cold PBS to remove the medium. Subsequently, RIPA buffer (150 mmol/L sodium chloride (NaCl), 2 mmol/L ethylenediaminetetraacetic acid (EDTA), 50 mmol/L Tris-HCl, pH 7.5) and lysis buffer (1% deoxycholic acid and 1% NP-40) were added. Protease inhibitor cocktail tablets (Bio-Rad Laboratories, USA) were also added. The cell lysates were then centrifuged at 12,000 × g for 15 min. The supernatant was further centrifuged at 4°C at 16,000 × g for 5 min to obtain a clear solution of the protein mixture. The protein mixture was used to measure the expression of p53, p21, Bcl-2, Bax and caspase-3 by Western blotting using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal antibody control. Total cell lysate protein doses were determined by assay dye (Bio-Rad Laboratories, USA) and absorption was measured at 595 nm. 60 µg of the extracted protein and GAPDH internal antibody control on sodium dodecyl sulfate (SDS) were loaded to 4%-12% Bis-tris acrylamide gel in 3-(N-Morpholino) propanesulfonic acid (NuPAGE MOPS) running buffer (Invitrogen ™ Life Technologies, Scotland, UK). After running the gel at 75 V for 3 h at room temperature, the resolved proteins were transferred onto a nitrocellulose membrane (SigmaAldrich, UK). The membranes were first incubated with an appropriate primary antibody (p53, Bcl-2, Bax, or GAPDH as a loading control and internal standard), followed by peroxidase conjugated anti-mouse IgG antibody (Sigma-Aldrich, UK). The membranes were washed and developed using a chemiluminescent reagent (Amersham, UK) prior to exposure to photographic films. The protein bands' intensities were scanned and quantified using a densitometer.
Statistical analysis
Data obtained in these experiments represented an average of different replicates which were evaluated using equal variance and paired with Student's t-test along with other statistical analyses using GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, CA, USA). 
Results
Response of breast epithelial cell lines to HBCa treatments
The response of breast cells towards various treatments was studied using MTT assay (Figure 2) . HBCa compounds showed different effects on cell proliferation after 48 h treatment. However, different doses of HBCa demonstrated that cell proliferation decreased as the dose Figure  2 ). In addition, the apoptotic response of normal MCF-10A cells and cancer cells (MDA-MB231 and MCF-7) to HBCa compounds were assessed in vitro after 48 h using annexin V/propidium iodide assay ( Figure 3A) . A clear dose-dependent response was observed for 2-, 3-and 4-HBCa compounds to induce total cell death, particularly in MDA-MB231 and MCF-7 breast epithelial cancer cells ( Figure 3B ). HBCa-treated MCF-10A, MDA-MB231 and MCF-7 cells showed a higher level of late apoptosis and necrosis of cells (60%-84%) than early apoptosis of cells (18%-40%). The highest total cell death (17.03%) occurred when MCF-7 cells were treated with 2.5 mmol/L 2-HBCa for 48 h ( Figure 3B 
The effects of HBCa on cell cycle
The regulation of the cell cycle in the HBCa-treated breast epithelial cells (MCF-10A, MDA-MB231 and MCF-7) was analyzed after 48 h. Flow cytometry was used to quantify the DNA content within the cells which indicated that the distribution of different phases of the cell cycle were dependent on both the breast cell line and the HBCa compounds ( Figure 4A ). The treatment of the normal cell line (MCF-10A) resulted in an accumulation of cells in the G0/G1 phase in a dose-dependent manner compared to the control. The DNA contents increased from 8% to 31.47%. 2-HBCa was more effective in arresting MCF-10A at G0/G1 phase than the 3-and 4-HBCa compounds. However, the effects of different HBCa doses did not show significant differences (p = Figure 5A ). Similar results were obtained when the breast cancer cells (MDA-MB231 or MCF-7) were treated with 2.5 mmol/L HBCa ( Figure  5B) . Furthermore, the treatment of MCF-7 cells at 0.5 mmol/L was more effective than 2-and 3-HBCa in manipulating the expression of both Bcl-2 and Bax. The reduction of the expressed Bcl-2 in MCF-7 cells was between 25% and 70%, while the increase in Bax expression was between 73% and 97% ( Figure 5B ). In addition, the apoptotic effects of HBCa compounds on breast epithelial cells indicated that the level of expressions of p53, p21 and caspase-3 were dependent on the type of cells. 3-HBCa was more effective than 2-and 4-HBCa. 4-HBCa was more effective in the breast cancer cells (MDA-MB231 and MCF-7) (Figures 5B and  C) . In MDA-MB231, the expression of p53, p21 and caspase-3 were 140%, 86% and 102%, respectively. Furthermore, 4-HBCa upregulated apoptosis-related proteins in MCF-7 by 146%, 168% and 158%, respectively. However, when the breast cells were treated with 2.5 mmol/L HBCa compounds, the expressions of the pro-and antiapoptotic cells were lowered within 60%-100%. In addition, the treatment of breast epithelial cells with 2.5 mmol/L HBCa induced irregular expression of the proand anti-apoptotic proteins.
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Discussion
Breast cancer is one of the most commonly diagnosed malignancies in women. Various strategies have been adopted to combat this disease. Chemotherapy is one of the main therapeutic strategies and it has attracted the interest of many researchers aiming to develop effective anticancer compounds. Various compounds including natural and synthetic have been studied. Among these HB compounds include the most common drugs acetylsalicylic acid (ASA) and its precursor 2-HBA, or also known as salicylic acid. Although ASA and 2-HBA exert some side effects, their derivatives exhibit less acidity and possess more apoptotic potential. For example, earlier work has highlighted the potential for 4-HBZn to induce apoptosis, particularly in primary CLL and other cancer cells [4, 16] . HBCa compounds have also shown their apoptotic potential in human fibrosarcoma HT-1080 cells [10] . Metal ions including calcium (Ca ) showed improved efficacy to various organic compounds against cancer cells. For example, the incorporation of Zn 2+ or Ca 2+ ions improved the apoptotic potentials of HBA compounds [4, 10, 16] . In addition, platinum-based anticancer drugs have proven to exert highly effective therapeutic potentials in various cancer types [17] . Thus, the incorporation of metal ions enhances the anticancer activity of organic compounds and may also be considered as a novel strategy for further development of anticancer drugs [18] [19] [20] . Our previous results [12, 13, 16] have encouraged us to investigate the apoptotic effects of HBCa compound on human's normal (MCF-10A) and breast epithelial cancer cell lines (MDA-MB231 and MCF-7) breast epithelial cells. The current study revealed that the treatment of these epithelial cells with HBCa compounds for 48 h has significantly induced cell death in a dose-dependent manner, as assayed by annexin V. The three HBCa compounds showed variable effectiveness in the normal breast epithelial cells and two breast cancer cell lines. The results may suggest the importance of metal-based compounds in the development of a new anticancer drug. It is clear that HBCa caused a notably higher proportion of cell death in breast cancer cells (MDA-MB231 and MCF-7) than in normal breast cells (MCF-10A). The results may encourage further studies in order to explore the anticancer function and potential of HBCa and its corresponding zinc analogues.
Chemotherapeutically, apoptosis is a novel strategy to kill cancer cells without affecting the neighboring normal cells [21] . Although physiological and drug-induced apoptosis lead to cell death, both are different in regards to initiating and proceeding apoptosis [22] . In both cases, apoptosis inhibits cell growth or proliferation which is associated with modulation of cell cycle check points. Our results showed that HBCa-treated MCF-10A, MDA-MB231 and MCF-7 cells arrested the cell cycle at G1/G0 after 48 h. Normal and cancer cells showed different responses to the increasing doses of HBCa compounds. Lower doses were more effective than higher doses when arresting normal MDA-MB231 cells at the G0/G1 phase. Similar results were obtained when proand anti-apoptotic proteins were investigated in HBCatreated breast cells. The response of cancer cells to different HBCa doses was dependent on the type of cancer cell line and HBCa compound. These results may suggest different cytotoxic mechanisms of the two doses (0.5 and 2.5 mmol/L). Perhaps, 2.5 mmol/L HBCa might cause cytotoxicity to the breast cells, causing cells to undergo cell death. Although, assessing the morphology remains the most significant way to differentiate between apoptosis and necrosis. The results obtained from annexin V and the cell cycle may explain why 2.5 mmol/L HBCa was less effective apoptotically than 0.5 mmol/L HBCa. 2.5 mmol/L HBCa showed a higher level of late apoptosis and necrotic cells. These results may also explain the cytotoxic effect of higher doses of HBCa compounds. This issue highlights the association between the level of doses used and the type of cell death occurring: apoptosis or necrosis. The processes of aponecrosis can occur independently, sequentially and simultaneously, partly depending upon the type and level of stimuli, including anticancer drugs [23] [24] [25] . Apoptosis occurs via ligand binding and protein cross-linking with FAS (intrinsic pathway) or tumor necrosis factor (TNF) (extrinsic pathway) receptors. Other cells have a default death pathway that must be blocked by a survival factor such as a hormone or growth factor [25] . However, it should be noted that due to the lack of phagocytic cells in in vitro culture conditions, apoptosis fragments lyse and induce secondary necrosis or post-apoptotic necrosis in a process similar to necrosis [26] . It may be possible that the higher level of HBCa compounds contributed to the intracellular Ca 2+ overload, causing post-apoptotic necrosis. Necrosis or death channel in the cytoplasmic membrane can be a result of colloid osmotic forces and entry of cations that cause swelling and ultimately rupturing [27] . This effect causes the permeability transition pores to open in the mitochondrial inner membrane in response to the stimuli of intracellular Ca 2+ ions leading to necrosis [28] . This is also partly due to the inhibition of adenosine triphosphate (ATP) production by glycolysis or oxi-doi: 10.18282/amor.v1.i2. 35 dative phosphorylation [27, 29] . In addition, the necrotic process is regulated by oxidative stress and p53 when the anticancer compound 2-phenylethynesulfonamide was used [30] . Reactive oxygen species (ROS) is often highly expressed in cancer cells as a by-product of oxidative phosphorylation [31] . The higher doses of HBCa may cause a further increase in the level of ROS, either by increasing the level of the oxidative stress or detoxification, in order to regulate cellular processes including cell survival. In both cases, the increased level of ROS production leads to the diversion of apoptosis into necrosis signaling. In this regard, a previous research reported the lack of antioxidants in the breast cancer cells [32] . Literature has demonstrated cross-links between apoptosis and the cell cycle through the molecular modulation of different proteins, including Cdks, p53, Bax and Bcl-2 [33−37] . Thus, the ideal approach to assess the apoptotic effects of HBCa compounds is to measure the expression of both pro-and anti-apoptotic-related proteins. The use of Western blots clearly indicated that 0.5 mmol/L HBCa showed upregulation of p53, p21, Bax and caspase-3, while the expression of the anti-apoptotic proteins showed that Bcl-2 was downregulated. These results may suggest that the HBCa-treated epithelial breast cells underwent apoptosis via the intrinsic pathway. This pathway involves the activation of caspase-9 and caspase-3 in response to anticancer chemotherapy, which is closely associated with the increase of the outer mitochondrial membrane permeability, regulated by the Bcl-2 family [38] . It mainly involves caspase-3, which specifically activates the endonuclease CAD and degrades chromosomal DNA within the nuclei, as well as causing chromatin condensation [25] . Previously, we showed that 4-HBZn induced apoptosis via the intrinsic pathway in CLL which is partially abrogated by the caspase-9 inhibitor (Z-LEHD.FMK) [4] . In conclusion, the apoptotic effects of 2-, 3-and 4-HBCa compounds were significantly lesser in the control samples and normal (MCF-10A) breast epithelial cells (MCF-10A) than the corresponding cancer cells (MAD-Mb231 and MCF-7). These compounds induced cell cycle arrest at G0/G1. HBCa compounds also upregulated pro-apoptotic proteins, p53, p21, Bax and caspase-3 and downregulated the antiapoptotic protein Bcl-2. These results may suggest the involvement of the intrinsic apoptotic mechanism.
Conclusion
The treatment of breast epithelial cells MCF-10A, MDA-MB231 and MCF-7 with 2-, 3-, and 4-HBCa for 48 h induced more apoptosis at 0.5 mmol/L but more secondary necrosis at 2.5 mmol/L. The cytotoxic effect of the higher dose of HBCa could be explained as these compounds may default the apoptotic pathway, leading cell death into necrosis. Therefore, further studies will be required to investigate the stimulation of cell death in breast cancer cells.
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